AI assistant
MTI — Interim / Quarterly Report 2022
Nov 30, 2022
52003_rns_2022-11-30_65e629c0-b679-4f65-b31d-5369ccb60e37.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
==> picture [721 x 136] intentionally omitted <==
==> picture [721 x 136] intentionally omitted <==
----- Start of picture text -----
2022 Investment Forum
----- End of picture text -----
Date: November 30, 2022
Disclaimer
-
The information contained in this presentation, including all forward-looking statements, is subject to change without notice, whether as a result of new information, future events or otherwise, and Microelectronics Technology Inc. ( the “Company”) undertakes no obligation to update or revise the information contained in this presentation.
-
Investors are cautioned not to place under reliance on these forward-looking statements, which are made as of the date of this presentation, and we assume no obligation to update or revise any forward-looking statement.
2 MTI CONFIDENTIAL
Agenda
-
Welcome & Opening Remark
-
2022 Q3 Financial Highlights
-
Market Status & Business Strategy
Taishin Securities Hualin Chi Eugene Wu
- Q & A
3 MTI CONFIDENTIAL
==> picture [721 x 136] intentionally omitted <==
2022 Q3 Financial Highlights
4 MTI CONFIDENTIAL
Consolidated Income Statement
| (in NT$M) | 2022 Q3 | % of Rev | 2021Q3 | % of Rev | YoY(%) | ||
|---|---|---|---|---|---|---|---|
| Revenue | 1,301 | 100 | 1,003 | 100 | 30 | ||
| Gross profit | 170 | 13 | 157 | 16 | 8 | ||
| Operating expense | 263 | 20 | 269 | 27 | (2) | ||
| R&D | 180 | 14 | 190 | 19 | (5) | ||
| S&M | 44 | 3 | 45 | 4 | (2) | ||
| G&A | 39 | 3 | 34 | 3 | 15 | ||
| Operating income | (93) | (7) | (112) | (11) | |||
| Non-operating income | 2 | 0 | (2) | (0) | |||
| Net income | (95) | (7) | (117) | (12) | |||
| Basic EPS (in NT$) | (0.40) | (0.51) |
5 MTI CONFIDENTIAL
Consolidated Income Statement
| (in NT$M) | 2022 Q3 YTD | % of Rev | 2021 Q3 YTD | % of Rev | YoY(%) | ||
|---|---|---|---|---|---|---|---|
| Revenue | 3,262 | 100 | 3,006 | 100 | 9 | ||
| Gross profit | 424 | 13 | 428 | 14 | (1) | ||
| Operating expense | 743 | 23 | 742 | 25 | 0 | ||
| R&D | 516 | 16 | 530 | 18 | (3) | ||
| S&M | 113 | 3 | 112 | 4 | 1 | ||
| G&A | 114 | 3 | 100 | 3 | 14 | ||
| Operating income | (319) | (10) | (314) | (10) | |||
| Non-operating income | (32) | (1) | 6 | 0 | |||
| Net income | (365) | (11) | (308) | (10) | |||
| Basic EPS (in NT$) | (1.55) | (1.35) |
6
MTI CONFIDENTIAL
Sales Revenue by Product
==> picture [721 x 346] intentionally omitted <==
----- Start of picture text -----
7
MTI CONFIDENTIAL
----- End of picture text -----
Consolidated Balance Sheet
| (in NT$M) | Sep. 30 2022 | Sep. 30 2022 | Dec. 31 2021 | Dec. 31 2021 | ||
|---|---|---|---|---|---|---|
| AMT | % | AMT | % | |||
| Cashand cashequivalent | 1,025 | 15 | 1,138 | 17 | ||
| Accounts receivable | 1183 | 17 | 1147 | 18 | ||
| , | , | |||||
| Inventory | 2,380 | 35 | 2,156 | 33 | ||
| Current assets | 4,710 | 69 | 4,564 | 70 | ||
| Total assets | 6,795 | 100 | 6,552 | 100 | ||
| Short term loan | 1,604 | 24 | 1,548 | 24 | ||
| Accountspayable | 963 | 14 | 1,127 | 17 | ||
| Current liability | 3,321 | 49 | 3,281 | 50 | ||
| Longterm loan | 648 | 10 | 628 | 10 | ||
| Non-current liability | 1,283 | 19 | 1,308 | 20 | ||
| Total liability | 4,604 | 68 | 4,590 | 70 | ||
| Total equity | 2,191 | 32 | 1,962 | 30 |
8 MTI CONFIDENTIAL
Consolidated Cash Flow Statement
| (in NT$M) | 2022 Q3 | 2022 Q2 | 2022Q1 | ||
|---|---|---|---|---|---|
| Beginningcash balance | 862 | 1,205 | 1,138 | ||
| Net income before tax | (91) | (128) | (133) | ||
| Depreciation & amortization | 56 | 53 | 52 | ||
| AR/AP/Inventory | 43 | (213) | (208) | ||
| Others | 111 | 54 | (209) | ||
| Operating activities inflow(outflow) | 119 | (234) | (498) | ||
| Financial assets at fair value throughprofit or loss | (1) | (1) | (31) | ||
| Capital expenditure | (73) | (40) | (47) | ||
| Investing activities inflow(outflow) | (74) | (43) | (78) | ||
| Short term loan | 122 | (198) | 131 | ||
| Longterm loan | (12) | 148 | (2) | ||
| Capital Injection | 0 | 0 | 519 | ||
| Financing activities inflow(outflow) | 109 | (65) | 633 | ||
| Endingcash balance | 1,025 | 862 | 1,205 |
9
MTI CONFIDENTIAL
Consolidated Cash Flow Statement
| (in NT$M) | 2022 Q1~Q3 | 2021Q1~Q3 | ||
|---|---|---|---|---|
| Beginningcash balance | 1,138 | 1,325 | ||
| Net income before tax | (351) | (308) | ||
| Depreciation & amortization | 161 | 142 | ||
| AR/AP/Inventory | (378) | (598) | ||
| Others | (44) | (125) | ||
| Operating activities inflow(outflow) | (613) | (889) | ||
| Financial assets at fair value throughprofit or loss | (33) | (20) | ||
| Capital expenditure | (160) | (161) | ||
| Investing activities inflow(outflow) | (195) | (179) | ||
| Short term loan | 55 | 576 | ||
| Longterm loan | 134 | 362 | ||
| Capital Injection | 519 | 0 | ||
| Financing activities inflow(outflow) | 677 | 870 | ||
| Endingcash balance | 1,025 | 1,117 |
10
MTI CONFIDENTIAL